Back to top
more

AZURRX BIOPHARM (AZRX)

(Delayed Data from NSDQ)

$2.55 USD

2.55
68,693

+0.05 (2.11%)

Updated May 3, 2019 03:59 PM ET

After-Market: $2.53 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Entero Therapeutics, Inc. [AZRX]

Reports for Purchase

Showing records 41 - 60 ( 134 total )

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 41

01/04/2021

Company Report

Pages: 6

Licenses Novel Niclosamide Forms for ICI Colitis & COVID-19 GI Infection

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 42

11/18/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 43

11/17/2020

Company Report

Pages: 6

3Q20: Phase 2 Single - Combination Therapy Data Catalysts Coming In 1H21

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 44

08/24/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 45

08/18/2020

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 46

08/17/2020

Company Report

Pages: 5

2Q20: Positive Combination Trial Interim, Phase 2b Monotherapy Trial Began

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 47

08/17/2020

Company Report

Pages: 6

2Q20 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 48

08/17/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 49

08/12/2020

Company Report

Pages: 7

Combo Therapy Positive Interim Data in Cystic Fibrosis; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 50

08/12/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 51

08/11/2020

Company Report

Pages: 6

Positive Interim Phase 2 MS1819 Data from First Cohort, Full Data in 1H21

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 52

08/11/2020

Company Report

Pages: 6

Positive Interim Phase 2 MS1819 Data from First Cohort, Full Data in 1H21

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 53

07/23/2020

Company Report

Pages: 5

Phase 2b Trial Initiated; Financing Completed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 54

05/20/2020

Company Report

Pages: 6

1Q20 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 55

05/04/2020

Company Report

Pages: 8

IRB Say?s Yes to Phase 2, OPTION-2

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 56

04/30/2020

Company Report

Pages: 6

OPTION 2 Trial Gets Therapeutics Development Network Support; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 57

04/22/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 58

04/22/2020

Company Report

Pages: 5

Anticipates Slight COVID-19 Delay to OPTION 2 Trial; Full Focus on MS1819

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 59

04/22/2020

Company Report

Pages: 6

Phase 2 OPTION 2 Trial Initiation on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 60

04/06/2020

Company Report

Pages: 6

French Research Tax Credit Strengthens Cash Position; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party
// eof